AI-Powered Stock Analysis & Investment Research

Analyze over 5,500 stocks using cutting-edge AI tools. Get real-time market insights, deep company fundamentals, and smarter investment decisions.

Screener Image

Direct Access To the Stock market

Trending Investment Case Today

Stock-Card

AGX

+13.74%
Stock-Card

THC

+17.26%
Stock-Card

GNRC

+17.93%
Stock-Card

BWA

+22.45%
Stock-Card

SW

+9.90%
Stock-Card

RIG

+10.29%
Stock-Card

VAL

+10.79%

How to find the best strategy for you ?

Card image cap

Value

Our factor investing score meticulously assesses the intrinsic value of each asset, providing invaluable insights into its potential for long-term growth.

Card image cap

Growth

With a keen focus on growth prospects, our factor investing score analyzes each asset's trajectory, offering strategic guidance for maximizing returns in dynamic market conditions..

Card image cap

Quality

With an emphasis on quality metrics, our factor investing score meticulously evaluates the fundamental strength and stability of each asset, safeguarding your portfolio against potential risks.

Card image cap

Volatility

By meticulously evaluating volatility, our factor investing score helps you navigate market turbulence, ensuring a balanced portfolio resilient to unpredictable fluctuations.

Card image cap

Momentum

Leveraging momentum analysis, our factor investing score identifies assets poised for upward trends, empowering you to capitalize on market momentum for optimized performance.

Card image cap

Yield

Focused on yield optimization, our factor investing score identifies assets with attractive income potential, enabling you to construct a diversified portfolio tailored to your income objectives.

Create a reliable strategy with the A-Score

Undervalued company with stable and reliable business like Warren Buffet

Get detailled Investment Case for more than 5500 Stocks

Image

Strong Company Updates

Get a complete corporate access : reliable, clear, and always available at the time you need it

Stock-Card
Earnings

Gilead Sciences(GILD): Gilead Sciences' Strong FY2025 Results Driven by HIV Sales Growth

Gilead Sciences reported robust financial performance for FY2025, with total product sales reaching $28.9 billion, up 1% from 2024. The growth was primarily driven by HIV sales, which increased 6% year-over-year to $20.8 billion. The company's base business revenue grew 4% to $28 billion, excluding the impact of the Part D redesign. The actual EPS came out at $1.86, beating estimates of $1.81. The company's product gross margin is expected to be approximately 87% in 2026.

550$ (-1.8%)

A-Score: 6.8/10

Feb -10
Stock-Card
Earnings

Ecolab(ECL): Ecolab's Strong 2025 Performance and Promising 2026 Outlook

Ecolab delivered a robust financial performance in 2025, with record-breaking sales margins, earnings per share, and free cash flow. In Q4, the company reported 15% adjusted EPS growth, driven by accelerating underlying sales growth and continued strong OI margin expansion. Organic sales grew 3%, driven by 3% value pricing and positive volume growth. The actual EPS came out at $2.08, slightly beating estimates of $2.07. For 2026, Ecolab expects 3% to 4% organic sales growth, with growth accelerating as the year progresses, driven by strengthening volume growth.

550$ (-1.8%)

A-Score: 5.2/10

Feb -10
Stock-Card
Earnings

Cincinnati Financial(CINF): Cincinnati Financial Corporation Delivers Strong FY2025 Results

Cincinnati Financial Corporation reported a net income of $2,400,000,000 for full year 2025, representing a 4% increase from 2024. The company's fourth quarter net income rose 67% to $676,000,000. Earnings per share (EPS) for the full year 2025 came in at $3.37, beating analyst estimates of $2.86. The property-casualty combined ratio was 94.9%, near the midpoint of the company's long-term average target range. Revenue growth was driven by a 14% increase in investment income and a 5% growth in consolidated property-casualty net written premiums.

550$ (-1.8%)

A-Score: 6.8/10

Feb -10
Register Now

Quality Equity Research. Easy Access

Get started with our cost-effective equity research

Monthly Annual Up to 30% Discount

Free Trial

FREE
7 Days
  • Unlimited access to Watchlist
  • Unlimited access to screener
  • Unlimited access to AI Assistant
  • Access to US Investment Case
  • API calls limited to 10/day
  • Request new coverage
  • Premium Support
Start Free Trial

Ultimate

$99.90
per month
  • Unlimited access to Watchlist
  • Unlimited access to screener
  • Unlimited access to AI Assistant
  • Unlimited access to Investment Case
  • API calls limited to 2500/minute
  • Request new coverage
  • Premium Support
Buy Now